Five datasets were constructed from ligand and bioassay result data from the literature. These datasets include bioassay results from the Ames mutagenicity assay, Greenscreen GADD-45a-GFP assay, Syrian Hamster Embryo (SHE) assay, and 2 year rat carcinogenicity assay results. These datasets provide information about chemical mutagenicity, genotoxicity and carcinogenicity.
Data source location
Discipline of Pharmacology, Blackburn Building, University of Sydney, Australia
Data accessibility Raw and processed data are presented as CSV and ARFF files, respectively, as supplementary data for this article
Value of the data
This article contains the largest public collection of ligands and results for the GreenScreen GADDα-45 and Syrian Hamster Embryonic Cell Transformation assays collated from previous literature to date.
A benchmark dataset of pharmaceutically relevant ligands for use in rat carcinogenicity QSAR models is presented and compared with ligands from regulatory domains.
Physiochemical descriptors were calculated from the SMILES structures and selected for QSAR model performance.
Data
The creation of a QSAR model for the 2-year rodent carcinogenicity bioassay is highly desirable since it is the gold standard for assessing potential chemical carcinogenicity. However, previous modelling efforts have been hampered due to data availability and reliability issues stemming from bioassay limitations such as low throughput, high cost, and modest reproducibility between laboratories and rodent species. The in vivo carcinogenicity datasets in this article are solely rat carcinogenicity outcomes due to previous literature finding the rat carcinogenicity bioassay produces better endpoint reliability in comparison to the mouse carcinogenicity bioassay. This article presents two rat carcinogenicity datasets from the regulatory toxicology and pharmaceutical safety chemical domains.
Genotoxicity occurs from chemicals acting with genomic mechanisms of toxicity and this has been associated with potential carcinogenicity. This endpoint type features many in vitro bioassays with larger libraries of screened molecules in comparison to in vivo rodent carcinogenicity bioassay data. QSAR models capable of utilizing this data in combination with rodent carcinogenicity data may address the limited applicability domain of the in vivo data. The data was exhaustively collated from the in vitro GreenScreen GADDα-45 and Syrian Hamster Embryonic bioassays from the literature. Previous literature found concordance between these bioassays and in vivo rodent carcinogenicity outcomes. The Ames Bacterial Mutagenicity Benchmark Dataset has also been included for comparison.
Experimental design, materials and methods

Dataset preparation
ISSCAN: 854 chemical database of in vivo rat carcinogenicity from [1] . PHARM: in vivo rodent carcinogenicity results on pharmaceutical chemicals from [2] . GreenScreen: 1415 GADD-45a-GFP assay results from [3] [4] [5] [6] [7] [8] [9] [10] . Syrian Hamster Embryonic: Data on 1415 chemicals extracted from [11, 12] . Ames: 6512 Ames results from [13] .
Dataset curation
SMILES structures were generated using ChemAxon JChem for Office from CAS Numbers or chemical names. These structures were curated using ChemAxon Standardizer to remove salts and solvents and aromatized.
Descriptor selection
The CfsSubsetEval algorithm [14] selected subsets of structural descriptors (generated by PaDEL Descriptor [15] ) for each dataset.
Applicability domain quantification
The applicability domain of each dataset compared to the PHARM dataset was quantified using leverage, Euclidean distance from centroid, and a variable knn-based distance [16] measures.
QSAR model Attribute Importance Scores
Attribute Importance Scores were calculated from each RandomForest QSAR model (Fig. 1,  Tables 1-7 ).
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